Janus Henderson Group
AVIR icon

Janus Henderson Group’s Atea Pharmaceuticals AVIR Stock Holding History

Janus Henderson Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35,909
Closed -$120K – 2601
2023
Q1 		$120K Buy
35,909
+17,769
+98% +$72.1K ﹤0.01% 2597
2022
Q4 		$87.2K Sell
18,140
-18,138
-50% -$91.8K ﹤0.01% 2357
2022
Q3 		$208K Buy
+36,278
New +$278K ﹤0.01% 2390

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group's AVIR Position: Q2 2023 in Review

Janus Henderson Group sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 35,909 shares — an estimated $120K sold.

Janus Henderson Group first reported a position in AVIR in Q3 2022 and held it in 3 quarters. The position peaked at $208K in Q3 2022. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

  • Janus Henderson Group reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Janus Henderson Group sold 35,909 Atea Pharmaceuticals shares in Q2 2023, an estimated $120K.
  • Janus Henderson Group first reported a position in Atea Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Janus Henderson Group's Atea Pharmaceuticals position peaked at $208K in Q3 2022.
  • 133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Janus Henderson Group's 13F filing for Q2 2023, filed 14 Aug 2023.